- Trials with a EudraCT protocol (369)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
369 result(s) found for: Experimental research.
Displaying page 1 of 19.
EudraCT Number: 2016-002663-33 | Sponsor Protocol Number: NUH-ALS-2015-04 | Start Date*: 2018-11-05 | |||||||||||
Sponsor Name:Alloksys Life Sciences BV | |||||||||||||
Full Title: Preventing Oxidative stress induced Ischemic Injury and Systemic Inflammation complications during and after invasive Cardiac surgery with Alkaline Phosphatase (APPIRED III) | |||||||||||||
Medical condition: systemic inflammation as side-effect of heart-lung machine during cardiac surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) NL (Completed) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003357-17 | Sponsor Protocol Number: Ketamin_SST01 | Start Date*: 2013-11-01 | ||||||||||||||||
Sponsor Name:Prof. Asbjørn Mohr Drewes | ||||||||||||||||||
Full Title: RESET Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of S-ketamine for pain treatment in chronic pancreatitis (RESET trial) | ||||||||||||||||||
Medical condition: Chronic Pancreatitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-000746-32 | Sponsor Protocol Number: 5-HT_CFM | Start Date*: 2008-04-23 |
Sponsor Name:Karolinska Institutet | ||
Full Title: Validation of experimental pain models as translational for craniofacial myalgia with respect to the influence of 5-HT, glutamate, cortisol and estradiol level | ||
Medical condition: Patients with craniomandibular myalgia (CM), i.e. with pain in the masster muscle and a diagnosis of myofascial pain according to the RDC/TMD criteria, and healthy subjects of both sexes, over 18 y... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003728-39 | Sponsor Protocol Number: OTMother2014 | Start Date*: 2014-12-16 |
Sponsor Name:Tampere University Hospital | ||
Full Title: Effects of maternal oxytocin on social information processing in mothers | ||
Medical condition: There are no medical conditions or diseases under investigation, participants are healthy volunteers. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006814-35 | Sponsor Protocol Number: MoodBugs_Rifaximin | Start Date*: 2022-09-27 |
Sponsor Name:KU Leuven | ||
Full Title: A randomized, triple-blind, placebo-controlled study on the effect of rifaximin on psychobiological functions in healthy men | ||
Medical condition: Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test whether rifaximin adminis... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002392-10 | Sponsor Protocol Number: S59302 | Start Date*: 2017-02-02 |
Sponsor Name:UZ Leuven | ||
Full Title: Reconsolidation interference versus retrieval interference as the basis for experimental amnesia in humans – The effect of drug state at memory retrieval | ||
Medical condition: Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test wether the internal drug ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004542-15 | Sponsor Protocol Number: SGN22E-003 | Start Date*: 2020-08-03 | |||||||||||||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||||||||||||
Full Title: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally a... | |||||||||||||||||||||||
Medical condition: Urothelial cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004169-34 | Sponsor Protocol Number: UoB1407 | Start Date*: 2012-02-07 |
Sponsor Name:University of Bristol | ||
Full Title: Effects of Varenicline and Cognitive Bias Modification on Neural Response to Smoking Cues | ||
Medical condition: Healthy volunteer trial: Neural responses to smoking cues Intended indication (Smoking cessation) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001976-39 | Sponsor Protocol Number: CHDR1227 | Start Date*: 2013-07-30 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: Randomized, open-label, crossover study into the contribution of the intestines and kidney in the diurnal variation of Levofloxacin pharmacokinetics | ||
Medical condition: The circadian variation in the relative contribution of intestinal uptake and renal elimination of levofloxacin | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000810-12 | Sponsor Protocol Number: CO41101 | Start Date*: 2019-12-09 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR META... | ||||||||||||||||||
Medical condition: Metastatic triple-negative breast cancer (TNBC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) FR (Completed) AT (Completed) PL (Completed) PT (Completed) IE (Prematurely Ended) ES (Completed) FI (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended) BG (Completed) DK (Completed) RO (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001718-13 | Sponsor Protocol Number: MP18 | Start Date*: 2019-10-18 |
Sponsor Name:MAPS Europe B.V. | ||
Full Title: An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Dis... | ||
Medical condition: post-traumatic stress disorder (PTSD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) CZ (Completed) NO (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-001626-22 | Sponsor Protocol Number: RML-TB | Start Date*: 2022-03-28 |
Sponsor Name:Vall d'Hebron Institute of Research | ||
Full Title: A Multicentre Controlled Open Randomized Clinical Trial to evaluate the efficacy and safety profile of an anti-TB drug combination based on High Dose Rifampicin, High Dose Moxifloxacin and Linezoli... | ||
Medical condition: Smear-positive rifampicin-sensitive pulmonary Tuberculosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003024-16 | Sponsor Protocol Number: ACT16482 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
Full Title: Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol | |||||||||||||
Medical condition: Plasma cell myeloma refractory | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) FR (Completed) GR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000109-66 | Sponsor Protocol Number: TPU-TAS-102-301 | Start Date*: 2012-12-10 | |||||||||||
Sponsor Name:Taiho Oncology, Inc. | |||||||||||||
Full Title: RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD CHEMOTHERAPIES | |||||||||||||
Medical condition: Refractory metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) ES (Completed) IE (Completed) CZ (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000317-22 | Sponsor Protocol Number: BRE-ASA01 | Start Date*: 2017-04-13 |
Sponsor Name:Linköping University | ||
Full Title: A pilot study of low dose acetylsalicylic acid (ASA) for reduction of breast density and inflammation | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005431-13 | Sponsor Protocol Number: OTMother2015 | Start Date*: 2015-01-13 |
Sponsor Name:Tampere University Hospital | ||
Full Title: Effects of maternal oxytocin on social information processing in mothers and infants | ||
Medical condition: There are no medical conditions or diseases under investigation, participants are healthy volunteers. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18, Adults | Gender: Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001316-29 | Sponsor Protocol Number: 205801 | Start Date*: 2019-03-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd. | |||||||||||||
Full Title: A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants | |||||||||||||
Medical condition: non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) SE (Completed) FR (Completed) DK (Prematurely Ended) IT (Completed) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002706-36 | Sponsor Protocol Number: VASOPRESSOR-LPS | Start Date*: 2016-01-06 |
Sponsor Name:Radboudumc | ||
Full Title: The effects of different vasopressors on the innate immune response during experimental human endotoxemia, a pilot proof-of-principle study | ||
Medical condition: Possible future indications: infectious diseases which require vasopressor therapy. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000777-80 | Sponsor Protocol Number: SENS111-202 | Start Date*: 2018-06-08 |
Sponsor Name:Sensorion | ||
Full Title: A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed... | ||
Medical condition: healthy volunteers (medicine for acute unilateral vertigo) | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003238-35 | Sponsor Protocol Number: 4_141221 | Start Date*: 2021-09-15 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Effects of supplemental oxygen on systemic and cerebral hemodynamics in experimental hypovolemia: A randomized, phase IV, crossover study to study the effect of supplemental oxygen vs. room air on ... | |||||||||||||
Medical condition: Hypovolemia is the condition under investigation. Hypovolemia is induced by the "lower body negative pressure" (LBNP)-model. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
